Here we show that in the liver of db/db mice, a murine model of obesity, type 2 diabetes, and dyslipidemia, the elevated activities of mitogen-activated protein kinases (MAPK; ERK1/2 and p38<sup>MAPK</sup>), and Akt/PKB are abolished by rosiglitazone-treatment, which normalizes blood glucose in db/db mice.